Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 10.66 [1][5]. Core Insights - The company reported a revenue of RMB 713 million in 2025, representing a year-on-year increase of 15.8%, with a loss of RMB 208 million. Adjusted loss, excluding the impact of the frontier technology business, was RMB 111 million, narrowing by 44.1% year-on-year. This performance aligns with the company's previous profit forecast [1]. - The growth in revenue and the reduction in loss are primarily attributed to the robust growth of the TAVR segment and significant profit increase from the TaurusTrio product, which is expected to contribute approximately 1,500 units in 2026 [1][2]. - For 2026, the TAVR segment is projected to achieve a revenue growth of 30%, with an estimated implantation volume exceeding 5,000 units. The neuro-interventional business is expected to maintain a stable revenue growth rate of 15-20% [1][2]. TAVR Segment Summary - In 2025, the TAVR segment generated revenue of RMB 290 million, with an implantation volume of 3,900 units, reflecting a year-on-year growth of 14.4%. The growth is driven by the rapid uptake of new generation products and hospital coverage [2]. - The segment is expected to see over 30% revenue growth in 2026, supported by a moderate price adjustment and the anticipated commercialization of the TaurusTrio product [2]. Neuro-Interventional Segment Summary - The neuro-interventional segment achieved revenue of RMB 423 million in 2025, with a profit of RMB 97.2 million, marking an 86.6% year-on-year increase. This growth is attributed to stable cash flow from traditional spring coils and increased market share from thrombectomy stents [3]. - The segment is projected to maintain a revenue growth rate of 15-20% in 2026, driven by the full coverage of procurement and the FDA approval of the DCwire product, which is expected to open up overseas markets [3]. Product Pipeline Summary - The company is advancing multiple product lines, including the HighLife and GeminiOne products, which are in various stages of clinical trials and registration. The TaurusNXT and GeminiOne TEER products are expected to be launched in 2026 [4]. Financial Forecast and Valuation - Revenue projections for 2026-2028 are estimated at RMB 909 million, RMB 1.252 billion, and RMB 1.636 billion, respectively. The net profit for 2026 is projected to be RMB 2.17 million, with significant growth expected in subsequent years [5][10]. - The DCF valuation method estimates a target price of HKD 10.66, reflecting adjustments in the company's cost of capital and growth assumptions [5][11].

Group 1 - The "Shockwave Valve Treatment System" developed by Zhejiang University School of Medicine and Peijia Medical has been selected for the National Medical Products Administration's innovative medical device special review procedure, marking a significant breakthrough in the treatment of aortic valve calcification in China [1][3] - This system represents a shift from "artificial valve replacement" to "autologous valve repair," addressing the durability issues of implants for younger patients and the surgical challenges for complex calcified cases [1][2] - The technology utilizes advanced imaging guidance and energy control to precisely focus shockwave energy, effectively loosening calcified lesions while protecting surrounding healthy tissue, thus avoiding long-term complications associated with traditional implants [2] Group 2 - The inclusion of the Shockwave Valve Treatment System in the innovative channel reflects regulatory recognition of its originality and clinical value, which will accelerate its clinical trial and registration process [3] - Peijia Medical aims to expedite the clinical transformation of this technology to benefit a wide range of patients, especially in the context of the growing global population suffering from heart valve diseases [3] - The breakthrough signifies a new height in China's medical device innovation and indicates a shift towards more precise, minimally invasive, and personalized treatment for heart valve diseases [3]

Market Performance - The Hang Seng Index (HSI) closed at 25,082, up 0.7% for the day and 25.0% year-to-date (YTD) [1] - The MSCI Hong Kong index increased by 1.4% for the day and 26.9% YTD [1] - The KOSPI index showed a significant YTD increase of 34.5%, closing at 3,228 [1] Commodity Prices - Brent Crude oil price decreased by 0.9% to US$66 per barrel, down 8.3% YTD [2] - Gold prices rose by 0.8% to US$3,396 per ounce, with a YTD increase of 29.4% [2] - The Baltic Dry Index (BDI) surged by 92.7% YTD, closing at 1,921 [2] Economic Indicators - US consumer credit total was reported at US$5.1 billion, below the consensus of US$7.4 billion [3] - The US CPI for urban consumers increased by 0.3% month-over-month and 2.7% year-over-year [3] - The US PPI Final Demand YoY increased by 2.3%, slightly below the consensus of 2.5% [3] Trade and Exports - China's exports grew by 7.2% YoY in July, surpassing the 5.2% growth in June [5] - Imports into China increased by 4.1% YoY in July, indicating a rebound from previous months [7] - The strong export growth to non-US regions helped offset declines in exports to the US due to increased tariffs [6] Corporate Insights - China Mobile reported a 6% YoY increase in Q2 earnings to RMB53.6 billion, exceeding market expectations [13] - Hua Hong Semiconductor's Q2 results showed a gross profit margin of 10.9%, driven by a 6% QoQ increase in wafer shipments [16] - BeiGene's Q2 revenue reached US$1.32 billion, a 42% YoY increase, with significant contributions from its key products [24]

Core Viewpoint - The Hong Kong innovative medical device sector has seen significant growth this year, with the Hang Seng Healthcare Index rising over 50% year-to-date, driven by profit recovery and valuation adjustments [1][3]. Group 1: Market Dynamics - The National Medical Products Administration (NMPA) has announced ten measures to support the innovation and development of high-end medical devices, further enhancing long-term investment expectations for innovative medical device companies [1][3]. - The current investment environment is warming, leading to increased focus on the validation of innovative technologies and their commercial potential [3][9]. Group 2: Company Performance - Peijia Medical (09996) has experienced a stock price increase of over 95% year-to-date, significantly outperforming the index and bringing its market capitalization to around HKD 5 billion [1][3]. - The company has established itself as a leading brand in the Chinese transcatheter aortic valve replacement (TAVR) market, with a market share increase from 5% in 2021 to over 25% currently [4][10]. Group 3: Product Development and Innovation - Peijia Medical is advancing its product pipeline, with its second-generation TAVI product nearing market approval and its third-generation product expected to enter the market in the first half of next year [4][10]. - The company has a robust pipeline that includes innovative technologies such as non-glutaraldehyde cross-linked valves and shockwave calcification reconstruction technology, positioning it well against competitors [10][12]. Group 4: Market Potential - The TAVR market in China is projected to grow significantly, with an expected compound annual growth rate (CAGR) of 36.6% from 2021 to 2030, reaching approximately 109.5 billion yuan by 2030 [9][11]. - The current TAVR penetration rate in China is only 5.7% of the global total, indicating substantial growth potential for the market [11]. Group 5: Future Outlook - Peijia Medical aims to solidify its position as the leading TAVR brand in China by expanding its product offerings and increasing market share to 25-30% by 2025 [4][12]. - The company is also pursuing international expansion, with plans to apply for CE certification for its products and engage in global clinical studies [12][13].